Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study-Reference-Cited by-同舟云学术

Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study

Published:2024-03 Issue:3 Volume:11 Page:e186-e195
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Bataller Alex,Montalban-Bravo Guillermo,Bazinet Alexandre,Alvarado Yesid,Chien Kelly,Venugopal Sangeetha,Ishizawa Jo,Hammond Danielle,Swaminathan Mahesh,Sasaki Koji,Issa Ghayas C,Short Nicholas J,Masarova Lucia,Daver Naval G,Kadia Tapan M,Colla Simona,Qiao Wei,Huang Xuelin,Kanagal-Shamanna Rashmi,Hendrickson Stephany,Ravandi Farhad,Jabbour Elias,Kantarjian Hagop,Garcia-Manero Guillermo

Funder

Genentech Inc

University of Texas MD Anderson Cancer Center

Astex Therapeutics Ltd

Publisher

Elsevier BV

Reference30 articles.

1. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management;Garcia-Manero;Am J Hematol,2023

2. Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens;Saber;Hematology (Am Soc Hematol Educ Program),2016

3. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study;Fenaux;Lancet Oncol,2009

4. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies;Damaj;J Clin Oncol,2012

5. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS;Gerds;Biol Blood Marrow Transplant,2012

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in the management of higher-risk myelodysplastic syndromes: future prospects;Leukemia & Lymphoma;2024-05-07

2. Latest Insights and Therapeutic Advances in Myelodysplastic Neoplasms;Cancers;2024-04-19

3. Decitabine plus cedazuridine and venetoclax: the promise of an all-oral therapy for patients with myelodysplastic syndromes and chronic myelomonocytic leukaemia;The Lancet Haematology;2024-03